Filana Therapeutics, Inc. (FLNA)vsRegeneron Pharmaceuticals Inc (REGN)
FLNA
Filana Therapeutics, Inc.
$1.44
-7.69%
HEALTHCARE · Cap: $77.78M
REGN
Regeneron Pharmaceuticals Inc
$686.36
+3.02%
HEALTHCARE · Cap: $74.13B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN appears more attractively valued with a PEG of 1.46. REGN earns a higher WallStSmart Score of 64/100 (C+).
FLNA
Hold36
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FLNA.
Margin of Safety
+51.7%
Fair Value
$1464.40
Current Price
$686.36
$778.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.5%
Areas to Watch
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : FLNA
The strongest argument for FLNA centers on Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Altman Z-Score, Market Cap, Profit Margin. Profitability is solid with margins at 29.6% and operating margin at 23.5%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : FLNA
The primary concerns for FLNA are PEG Ratio, Revenue Growth, EPS Growth.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
FLNA profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.40 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 36/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Filana Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach, Florida.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?